RetiSpec

RetiSpec is a Toronto-based medical artificial intelligence company that aims to enable widespread, early, and accurate detection of neurodegenerative disease biomarkers through simple eye examinations. RetiSpec's AI solution, applied to non-invasive retinal images, provides real-time results at the point of care. RetiSpec’s first clinically validated AI is designed to predict amyloid burden to help assess Alzheimer’s disease. RetiSpec’s AI solutions are currently for research use only.